ABL1 (F317I)
Sign in to save this workspaceABL1 · Variant type: point · HGVS: p.F317I
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Ponatinib | 99.5% | 0.5% | 78.23 |
| 2 | Bosutinib | 99.2% | 0.8% | 87.22 |
| 3 | Dasatinib | 98.8% | 1.2% | 87.97 |
| 4 | Tivozanib | 97.5% | 2.5% | 92.42 |
| 5 | Brigatinib | 97.0% | 3.0% | 82.96 |
| 6 | Nilotinib | 96.2% | 3.8% | 96.49 |
| 7 | Alectinib | 96.0% | 4.0% | 95.49 |
| 8 | Axitinib | 91.2% | 8.8% | 93.23 |
| 9 | Mobocertinib | 90.4% | 9.6% | 97.22 |
| 10 | Vandetanib | 80.7% | 19.3% | 95.74 |
| 11 | Repotrectinib | 78.3% | 21.7% | 84.21 |
| 12 | Nintedanib | 76.8% | 23.2% | 90.23 |
| 13 | Alpelisib | 74.5% | 25.5% | 97.22 |
| 14 | Pacritinib | 70.8% | 29.2% | 88.64 |
| 15 | Lenvatinib | 67.4% | 32.6% | 97.74 |
| 16 | Fedratinib | 66.0% | 34.0% | 96.21 |
| 17 | Canertinib | 61.8% | 38.2% | 96.49 |
| 18 | Imatinib | 57.6% | 42.4% | 99.00 |
| 19 | Afatinib | 56.0% | 44.0% | 98.50 |
| 20 | Ripretinib | 54.2% | 45.8% | 92.95 |
| 21 | Erdafitinib | 52.6% | 47.4% | 95.71 |
| 22 | Ceritinib | 49.8% | 50.2% | 95.44 |
| 23 | Selpercatinib | 45.1% | 54.9% | 96.72 |
| 24 | Dacomitinib | 44.9% | 55.1% | 97.99 |
| 25 | Entrectinib | 43.8% | 56.2% | 93.69 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Ponatinib | 99.5% | 100.0% | -0.5% |
| Bosutinib | 99.2% | 99.7% | -0.5% |
| Dasatinib | 98.8% | 98.6% | +0.2% |
| Tivozanib | 97.5% | 95.8% | +1.7% |
| Brigatinib | 97.0% | 82.8% | +14.1% |
| Nilotinib | 96.2% | 98.0% | -1.8% |
| Alectinib | 96.0% | — | — |
| Axitinib | 91.2% | 99.4% | -8.2% |
| Mobocertinib | 90.4% | — | — |
| Vandetanib | 80.7% | 95.7% | -15.0% |
| Repotrectinib | 78.3% | 93.6% | -15.3% |
| Nintedanib | 76.8% | 99.9% | -23.1% |
| Alpelisib | 74.5% | — | — |
| Pacritinib | 70.8% | 92.0% | -21.2% |
| Lenvatinib | 67.4% | 76.3% | -8.9% |
| Fedratinib | 66.0% | 82.7% | -16.7% |
| Canertinib | 61.8% | 91.6% | -29.8% |
| Imatinib | 57.6% | 86.2% | -28.5% |
| Afatinib | 56.0% | — | — |
| Ripretinib | 54.2% | 82.9% | -28.6% |
| Erdafitinib | 52.6% | 90.9% | -38.4% |
| Ceritinib | 49.8% | — | — |
| Selpercatinib | 45.1% | — | — |
| Dacomitinib | 44.9% | 80.8% | -35.9% |
| Entrectinib | 43.8% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| haematopoietic_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.8ms